Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
24 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
European Research Infrastructure on Highly Pathogenic Agents from Elsene, company number BE0679481238, closed financial year 2025 with a result of € 113,901 after tax. For that financial year European Research Infrastructure on Highly Pathogenic Agents recorded a gross margin of € 1.1 million and equity of € 2.1 million. Compared with financial year 2024, the result moved from € 473,212 to € 113,901. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 2.1 million
▲ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 113,901
▼ 76% vs 2024
Profit after tax over the fiscal year.
€ 5.6 million
▲ 41% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
10
▼ 1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 994,958
▲ 8% vs 2024
€ 99,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 19,108
▲ 68% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 132,995
▼ 14% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 986,636 | € 1,044,933 | € 1,366,116 | € 1,083,266 | ▼ 21% |
| Profit after taxes | € 248,541 | € 158,952 | € 473,212 | € 113,901 | ▼ 76% |
| Equity | € 1,306,688 | € 1,465,640 | € 1,938,851 | € 2,052,753 | ▲ 6% |
| Total debts | € 12,491,700 | € 9,845,896 | € 4,532,989 | € 5,543,608 | ▲ 22% |
| Cash | € 13,231,226 | € 10,542,313 | € 3,941,873 | € 5,554,046 | ▲ 41% |
| Retained profit | € 1,306,688 | € 1,465,640 | € 1,938,851 | € 2,052,753 | ▲ 6% |
| Balance sheet total | € 13,798,388 | € 11,311,536 | € 6,471,840 | € 7,596,361 | ▲ 17% |
| Employees (FTE) | 7.5 | 9 | 11 | 10 | ▼ 1 |
By gross margin, European Research Infrastructure on Highly Pathogenic Agents ranks 1st of 8 companies with main activity “Speur- en ontwikkelingswerk op biotechnologisch gebied” in Elsene that publish figures (fiscal year 2025).
Key figures of European Research Infrastructure on Highly Pathogenic Agents, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about European Research Infrastructure on Highly Pathogenic Agents the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to European Research Infrastructure on Highly Pathogenic Agents?
What happened at European Research Infrastructure on Highly Pathogenic Agents in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Mari Gomes Abreu dos Santos Cristina stepped down as director. NBB
- Pieter Leyssen stepped down as director. NBB
- Vincent Lotteau stepped down as director. NBB
- Josiane Theuns Van Vliet stepped down as director. NBB
- Enrico Giardi stepped down as director. NBB
- Zoltan Kis stepped down as director. NBB
- Jonathan Ewbank stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 113,901 (▼ 76% vs 2024). filed late Source: NBB ↗
In short
From € 248,541 profit in 2022 to € 113,901 profit in 2025.
Paid € 63,928 in corporate taxes since 2022.
Best year ever: 2024, with € 473,212 profit.
On average € 108,300 of value added per employee in 2025.
Management
Directors
According to the 2025 annual accounts
Andreas Brave
Director
since 2023 · until 2026
Mari Gomes Abreu dos Santos Cristina
Director
since 2022 · until 2028
Josiane Theuns Van Vliet
Director
since 2024 · until 2027
Isabel Jado Garcia
Director
since 2023 · until 2026
Pieter Leyssen
Director
since 2022 · until 2028
Enrico Giardi
Director
since 2024 · until 2027
Zoltan Kis
Director
since 2024 · until 2027
Kurt Zatloukal
Director
since 2023 · until 2026
Jonathan Ewbank
Autre fonction
since 2021 · until 2026
Vincent Lotteau
Director
since 2023 · until 2028
Establishments
Establishment units
Physical locations of this company
Troonstraat 98 box B4
1050 Elsene
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 24 companies are registered at this address.
All companies at this address →Europa Pro Vita
Réseau Européen du Monde Rural - TERN - Trans European Rural Network
Alzheimer Europe
POLIS
€ 2.6 million gross margin · 2025
Association of European-level Research infrastructure Facilities
+19 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Elsene
Same main activity (Speur- en ontwikkelingswerk op biotechnologisch gebied), 14 active companies in Elsene, largest first.
€ 18.9 million revenue · 2025
€ 616,298 gross margin · 2024
€ 104,857 gross margin · 2025
€ 73,605 gross margin · 2025
€ 4,192 gross margin · 2025
€ -5,087 gross margin · 2025
Details
- Company number
- 0679.481.238
- VAT number
- BE 0679.481.238
- Registered office
- Troonstraat 98 bus B4, 1050 Elsene
- Names & denominations
- European Research Infrastructure on Highly Pathogenic Agents · ERINHA
- Enterprise type
- Rechtspersoon
- Legal form
- International non-profit association
- Legal situation
- Normale toestand
- Start date
- 1 August 2017
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Beroepsopleiding
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige gespecialiseerde wetenschappelijke en technische activiteiten